Trial Profile
A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Assess the Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs HTL 18318 (Primary)
- Indications Lewy body disease
- Focus Adverse reactions
- Sponsors Heptares Therapeutics; Sosei
- 30 Sep 2019 Status changed from suspended to withdrawn prior to enrolment.
- 07 May 2019 Planned initiation date changed from 1 Aug 2018 to 1 Jul 2019.
- 18 Sep 2018 Status changed from recruiting to suspended, as reported in the Sosei media release.